Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286533 | 0.87 | ESR1 (0.48) | ESR1MEN1KMT2AF2SMN1; SMN2 | |
| SCHEMBL2754229 | 0.84 | TSPO (0.52) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30994793 | 0.82 | ESR1 (0.49) | ESR1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL10941845 | 0.82 | ESR1 (0.49) | ESR1MEN1KMT2AF2SMN1; SMN2 | |
| SCHEMBL11250 | 0.81 | ALDH1A1 (0.51) | ESR1MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL11722894 | 0.81 | MEN1 (0.48) | ESR1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL2754152 | 0.79 | TSPO (0.45) | KMT2ASMN1; SMN2POLBCTSDCA12 | |
| SCHEMBL7880045 | 0.79 | CA12 (0.45) | ESR1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL2754185 | 0.79 | CYP3A4 (0.58) | MEN1KMT2AF2POLBLMNA | |
| SCHEMBL6695226 | 0.79 | F2 (0.46) | ESR1MEN1KMT2AF2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20060019963-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-6670394-B1 | Chronic obstructive pulmonary disease; phosphodiesterase isozyme denominated 4; compound preferentially binding to low affinity binding site; selectivity ratio (HPDE 4/LPDE 4) greater than 0.1 shows great improvement over Rolipram | SMITHKLINE BEECHAM CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-6555576-B1 | Administering selective inhibitors of phosphodiesterase isozyme denominated 4 (PDE 4) such as cis-(4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate) | SMITHKLINE BEECHAM CORPORATION | 2003-04-29 | — | — | US | disclosed |
| US-6143782-A | BRONCHODILATOR FOR INHIBITING PDE IV CATALYSTS AND BINDING RROLIPRAM AND ADMINISTERING | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-5998428-A | ANTIINFLAMMATORY AGENT; SIDE EFFECT REDUCTION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | ESR1 2919/4885MEN1 1410/4885KMT2A 732/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ESR1 1884/4885MEN1 1228/4885KMT2A 977/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | ESR1 2919/4885MEN1 1410/4885KMT2A 732/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ESR1 2988/4885MEN1 1333/4885KMT2A 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.